Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on Wednesday, May 31st, at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.j.

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

McDonald's

Investors wanting to enjoy steady and consistent income should consider dividend aristocrats. In fact, even in these chaotic times, dividend investing will ensure that your money continues to grow, no matter what.

3 Dividend Aristocrats to Buy for Consistent Income

J&J reported an unprofitable quarter in Q1 due to a $6.9 billion charge related to legal expenses. The business is expecting a strong year overall, and there are growth opportunities ahead in the long run.

Are Investors Undervaluing Johnson & Johnson's Stock?

Gilead Sciences

Humana

Moderna

Pfizer

UnitedHealth Group

The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U.S. economy, with many medical companies included in indexes like the S&P 500.

6 Best Healthcare Stocks to Buy Right Now

Johnson & Johnson's sales and earnings moved higher in the first quarter. The company's payout ratio is manageable enough to support future dividend growth.

Want Consistently Growing Passive Income? Buy Johnson & Johnson Stock

Kenvue

Are signs of life emerging from the moribund IPO market? If Johnson & Johnson (NYSE:JNJ)'s corporate advisors are correct, then, yes, possibly.

Does Johnson & Johnson's Kenvue IPO signal signs of life for US IPO market?

Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50.

Johnson & Johnson aims to raise $3 billion in Kenvue IPO

Johnson & Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an initial public offering later this year. J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock.

Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPO

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is curre.

Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow

Bank of America

NVIDIA

And we answer listener questions about retirement accounts, buying stock in your employer, and more.

Investors Discuss News From Bank of America and Johnson & Johnson

Apple

Amazon

American Express

D.R. Horton

Intuitive Surgical

Lululemon Athletica

Netflix

Procter & Gamble

Tractor Supply

Tesla

The "Motley Fool Money" crew kicks things off with a look at what's going on with Netflix.

Wall Street Headlines, International Investing, and Stocks to Watch

Coca-Cola

Investing in the stock market to derive a stable income in the form of dividends can be a complex task, with a myriad of options to choose from. The article explores the top three dividend companies worth considering for investors seeking stability and sustainability in their dividends.

The 3 Greatest Dividend Stocks to Buy Now

Cancer victims on Monday urged a U.S. judge to dismiss a Johnson & Johnson subsidiary's second bankruptcy filing, saying that the company is abusing the bankruptcy system in its renewed attempt to resolve tens of thousands of lawsuits alleging that J&J's baby powder and other talc products caused cancer.

Cancer victims urge US judge to dismiss J&J talc unit's second bankruptcy -court document

J&J's consumer health unit Kenvue aims to raise $3.5 billion or more in the initial public offering, sources told the Wall Street Journal.

Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says

Johnson & Johnson (NYSE:JNJ) is reportedly discussing the spin-off and initial public offering (IPO) of its consumer business Kenvue with investors, in a move set to test the waters of the subdued market. Kenvue will meet with investors as early as Monday to discuss the float, according to the Wall Street Journal, in a bid to raise over US$3.5bn on the New York Stock Exchange in the coming weeks.

Johnson & Johnson to eye up IPO market with consumer brand spin-off

Johnson & Johnson is reportedly readying an investors roadshow to take its commercial healthcare unit public. According to a Sunday (April 23) Wall Street Journal (WSJ) report, sources familiar with the matter say the company could begin meeting with investors as early as Monday (April 24) as it prepares for an initial public offering (IPO).

Johnson & Johnson Prepares to Test IPO Waters

Kenvue plans to start meeting with prospective investors as early as Monday.

J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market

J&J has proved that paying out dividends is important to the company. The big pharma player paid out $2.9 billion to shareholders in the first quarter.

If You're a Dividend Investor, You'll Love This News From Johnson & Johnson

Invesco S&P 500 Equal Weight Health Care ETF

Thermo Fisher Scientific

Zimmer Biomet Hlds

While still sporting a modest year-to-date loss, the S&P 500 Health Care Index is higher by 4.44% over the past month, and with the healthcare sector's reputation for defensive and quality traits, it could be a refuge for market participants if broader market volatility creeps higher.

Some of the Top Healthcare Companies Reside in this ETF

AbbVie

Embecta Corp

Johnson & Johnson just raised its quarterly dividend for the 61st straight year. AbbVie is counting on Skyrizi and Rinvoq and its deep pipeline to help replace lost revenue from Humira.

3 Top Dividend Kings to Buy for the Long Haul

Camden Property

Enterprise Products Partners

Enterprise Products Partners has the best credit rating in the midstream sector. Johnson & Johnson has a better bond rating than the U.S. government.

3 Very Low-Risk Ways to Invest $1,000 Right Now

J&J plans to spin off one of its businesses -- which could lead to more growth ahead. The consumer health business is well-known but makes up a small share of the company's total revenue.

Johnson & Johnson Stock: Should You Buy Before This Big Transition?

Leadership committee seeks to bring resolution to decade-long legal battle ST. LOUIS , April 21, 2023 /PRNewswire/ -- Lawyers representing approximately 55,000 plaintiffs in the litigation against Johnson & Johnson (NYSE: JNJ) over its cancer-causing talcum powder products have formed an Ad Hoc Committee to support an $8.9 billion deal that would end a decade-long legal battle against the pharmaceutical giant.

Plaintiffs' Attorneys Representing Talc-Cancer Victims Form Ad Hoc Committee to Support J&J Settlement

Lowe's

Altria

3 Best Dividend Kings For The Rest Of 2023.

3 Best Dividend Kings For The Rest Of 2023

Johnson & Johnson (NYSE:JNJ) said a US judge has temporarily halted most of the tens of thousands of lawsuits alleging the company's talc products, including baby powder, caused cancer, Reuters has reported. The decision will pause most of the litigation while J&J tries to reach a permanent settlement with current plaintiffs and sets aside money for future lawsuits.

News for Johnson & Johnson Stock (JNJ)